Archives
-
Thiothixene: From D2 Blockade to Efferocytosis
2026-10-01
Thiothixene is more than a conventional dopamine receptor antagonist. Its established role in psychotic disorder therapy now intersects with macrophage efferocytosis, vitamin A signaling, and translational neuroimmune research. This article examines how its D2 and 5-HT2A pharmacology may be studied alongside Stra6l and arginase 1 biology, while using recent FGFR1-focused schizophrenia genetics to frame a disciplined path from target discovery to experimental validation.
-
Vitamin C Workflows for Senescence and Cancer
2026-10-01
Vitamin C enables a controlled comparison between oxidative-stress rescue in senescent HEI-OC1 cells and concentration-dependent anticancer responses. This practical guide covers preparation, pathway-focused controls, assay design, and troubleshooting for reproducible ascorbic acid experiments.
-
Thiothixene Drives Macrophage Efferocytosis
2026-09-30
A 2025 Science Signaling study identifies Thiothixene as a candidate proefferocytic drug that stimulates mouse and human macrophages to clear apoptotic and lipid-laden cells. The work connects dopamine signaling pathway modulation with Stra6L-dependent Arginase 1 induction and offers a mechanistic framework for testing continual efferocytosis without implying clinical efficacy beyond established psychotic disorder therapy.
-
Cabazitaxel (XRP6258) Workflow Guide
2026-09-30
Cabazitaxel (XRP6258, SKU B2157) supports controlled cell-based studies of antiproliferative responses, microtubule dynamics disruption, and taxane-resistant cancer models. It is intended for DMSO- or ethanol-based preparation and should not be prepared directly in water or stored long-term as a solution.
-
AAL-993: Translating VEGF Receptor Biology
2026-09-29
A mechanistic and translational guide to using AAL-993 as a selective VEGF receptor inhibitor, connecting biochemical potency and melanoma models with disciplined tumor angiogenesis research and carefully bounded exploration of glioma biology.
-
Vitamin C in HEV Organoid Assays
2026-09-29
Vitamin C and ascorbic acid can be evaluated more rigorously in hepatitis E organoid systems when tissue complexity, viral replication, and host injury are separated. This article translates a landmark HEV organoid model into practical assay decisions while distinguishing established evidence from exploratory antiviral research.
-
DeferoxamineB in Ferroptosis Assays
2026-09-28
DeferoxamineB is a practical iron-axis probe for separating ferroptosis from copper-driven and general cytotoxic effects. This workflow shows how to use Deferoxamine as a rescue control, dose-optimization tool, and mechanistic companion to metabolic cancer models.
-
Amplex Red: Interpreting Peroxidase Signals
2026-09-28
Amplex Red is more than a sensitive hydrogen peroxide reporter: its signal reflects the chemistry and biology of a coupled reaction. Explore how to interpret that signal, what a CYP119 screening study revealed, and how to design experiments that distinguish peroxide-dependent activity from broader biological effects.
-
Multilineage Organoids Reveal HEV Tissue Tropism
2026-09-27
This study establishes induced pluripotent stem cell-derived liver, intestinal and brain organoids as models that support propagation of hepatitis E virus (HEV) genotypes 1, 3 and 4, revealing infection across multiple cell lineages. The models also capture organ-specific injury and partial responses to ribavirin, creating a platform for studying HEV biology and evaluating antiviral approaches in human tissue-like systems.
-
PEP Restricts cGAS Inflammation in Aging
2026-09-26
The study identifies phosphoenolpyruvate (PEP) as an age-associated glycolytic metabolite that can competitively inhibit cGAS and limit chronic inflammation. Its mouse and human findings suggest that the timing of PEP decline may matter for healthy-aging research, while the Alzheimer’s disease results remain preclinical.
-
Docetaxel Resistance: Read Beyond Cell Killing
2026-09-25
Docetaxel (Taxotere) is more than a mitotic cytotoxic agent: its response can reveal how drug efflux reshapes cancer-cell sensitivity. Explore a resistance-focused framework connecting microtubule stabilization, P-glycoprotein, p38 MAPK, and apoptosis readouts.
-
Thiothixene and Macrophage Clearance Capacity
2026-09-25
Thiothixene is a typical antipsychotic agent with an emerging role in macrophage efferocytosis research. This article focuses on how to interpret clearance capacity, design informative assays, and distinguish preclinical immune findings from schizophrenia treatment claims.
-
RQ3025 Bivalent mRNA Vaccine: Preclinical Evidence
2026-09-24
Preclinical testing of RQ3025 suggests that a bivalent mRNA design incorporating shared spike mutations can induce neutralizing responses across multiple SARS-CoV-2 variants in several animal models. The findings support further evaluation of multivalent vaccine strategies, while remaining preliminary evidence that does not establish safety or effectiveness in people.
-
LPS Protects Macrophages from Antitumor Drug Injury
2026-09-24
A 2026 study reports that lipopolysaccharide (LPS) protects RAW264.7 macrophages from antitumor drug–associated damage, with results implicating system Xc−-linked glutathione synthesis and ABCC1-sensitive processes. The findings connect inflammatory stimulation to macrophage drug tolerance, but do not establish that leukotriene receptor signaling explains the protection or that the mechanism applies in vivo.
-
Thiothixene: Practical Workflows for Efferocytosis
2026-09-23
Thiothixene offers macrophage researchers a way to test efferocytosis alongside its established dopamine-receptor pharmacology. This guide turns the reported 2 μM in vitro use into a controlled assay workflow and keeps cell-based findings distinct from human pharmacokinetic evidence.